ArticleAmerican journal of respiratory and critical care medicine2021
Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.0field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 50 citations in OpenAlex.
- Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9.Scientific reports · 2021Trial
- Extracellular matrix and proteolysis: mechanisms driving irreversible changes and shaping cell behavior.The FEBS journal · 2026Review
- The network pharmacology prediction and experiment validation of Astragalus membranaceus for alleviating silicosis fibrosis via decreasing MMP9 and EGFR expression.Scientific reports · 2026Article
- Review
- Matrix Metalloproteinase-9 (MMP-9) as a Therapeutic Target: Insights into Molecular Pathways and Clinical Applications.Pharmaceutics · 2025Review
- A single-cell transcriptomic atlas reveals senescence and inflammation in the post-tuberculosis human lung.Nature microbiology · 2025Article
- Article
- Combination therapy blocking TNF superfamily members 14 and 15 reverses pulmonary fibrosis.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Shared immunological pathways in rheumatoid arthritis-related interstitial lung disease.Frontiers in immunology · 2025Review
- Natural products for anti-fibrotic therapy in idiopathic pulmonary fibrosis: marine and terrestrial insights.Frontiers in pharmacology · 2025Review
- Identification of PANoptosis-related genes for idiopathic pulmonary fibrosis by machine learning and molecular subtype analysis.Scientific reports · 2024Article
- A novel pulmonary fibrosis NOD/SCID murine model with natural aging.BMC pulmonary medicine · 2024Article
- Anti-CCL2 therapy reduces oxygen toxicity to the immature lung.Cell death discovery · 2024Article
- Zinc Iodide Dimethyl Sulfoxide Reduces Collagen Deposition by Increased Matrix Metalloproteinase-2 Expression and Activity in Lung Fibroblasts.Biomedicines · 2024Article
- TGF-β signaling in health, disease, and therapeutics.Signal transduction and targeted therapy · 2024Review
- Human apical-out nasal organoids reveal an essential role of matrix metalloproteinases in airway epithelial differentiation.Nature communications · 2024Article
- Article
- Licoricesaponin G2 ameliorates bleomycin-induced pulmonary fibrosis via targeting TNF-α signaling pathway and inhibiting the epithelial-mesenchymal transition.Frontiers in pharmacology · 2024Article
- SRC and TKS5 mediated podosome formation in fibroblasts promotes extracellular matrix invasion and pulmonary fibrosis.Nature communications · 2023Article
- Amelioration of Pulmonary Fibrosis by Matrix Metalloproteinase-2 Overexpression.International journal of molecular sciences · 2023Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 5 institutions in 1 country.
Milena S EspindolaWomen's Guild Lung Institute, Pulmonary & Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
David M HabielWomen's Guild Lung Institute, Pulmonary & Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Ana Lucia CoelhoWomen's Guild Lung Institute, Pulmonary & Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Barry StrippWomen's Guild Lung Institute, Pulmonary & Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
William C ParksWomen's Guild Lung Institute, Pulmonary & Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Justin OldhamDivision of Pulmonary & Critical Care Medicine, University of California at Davis, Sacramento, California.
Fernando J MartinezWeill Cornell Medical College, Cornell University, New York, New York.
Imre NothDivision of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia; and.
David LopezDepartment of Biology, Gilead Sciences, Inc., Foster City, California.
Amanda Mikels-VigdalDepartment of Biology, Gilead Sciences, Inc., Foster City, California.
Victoria SmithDepartment of Biology, Gilead Sciences, Inc., Foster City, California.
Cory M HogaboamWomen's Guild Lung Institute, Pulmonary & Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Cedars-Sinai Medical Center · USGilead Sciences (United States) · USCornell University · USUniversity of California, Davis · USUniversity of Virginia · US
Funding
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUH3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2021 to 2025
$11.6MArchitectural structure and regulation of TOLLIP in IPFR01HL130796 · NHLBI · UNIVERSITY OF VIRGINIA · PI NOTH, IMRE · 2016 to 2019
$3.1MControl of Macrophage Activation in Lung DiseaseR01HL141078 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI PARKS, WILLIAM C · 2018 to 2021
$2.4MInnate DNA sensing in rapidly progressing IPFR01HL123899 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI HOGABOAM, CORY M · 2015 to 2018
$2.0MElucidating the Genomic Determinants of Outcomes in Idiopathic Pulmonary FibrosisK23HL138190 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OLDHAM, JUSTIN M · 2017 to 2021
$914kNHLBI NIH HHS K23 HL138190NHLBI NIH HHS R01 HL123899NHLBI NIH HHS R01 HL130796NHLBI NIH HHS R01 HL141078NHLBI NIH HHS UH3 HL145266
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntibodies, Monoclonal, HumanizedCaliforniaEpithelial CellsFemaleGene Expression RegulationHumansIdiopathic Pulmonary FibrosisMatrix Metalloproteinase 9MiceMichiganModels, AnimalProteomicsUnited StatesAntibodies, Monoclonal, HumanizedMatrix Metalloproteinase 9airway basal cellsandecaliximabidiopathic pulmonary fibrosismetalloproteinase 9type I IFNs
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.